FDA Signals New Testosterone Pathway
Agency invites sponsors to pursue low libido indication
By
Kathryn Wighton
April 16, 2026
Clinical Scorecard: FDA Signals New Testosterone Pathway
At a Glance
Category Detail
Condition Idiopathic hypogonadism with low libido Key Mechanisms Testosterone replacement therapy to address low testosterone levels without identifiable etiology Target Population Men with idiopathic hypogonadism experiencing decreased libido Care Setting Clinical settings managing male hypogonadism and sexual health
Key Highlights
FDA encourages sponsors to pursue new indication for TRT in men with idiopathic hypogonadism and low libido Current TRT approvals limited to hypogonadism with structural or genetic causes Approval requires substantial evidence of safety and effectiveness from well-controlled clinical trials Guideline-Based Recommendations
Diagnosis
Identify men with low testosterone levels and decreased libido without identifiable structural or genetic causes Management
Consider testosterone replacement therapy for men with idiopathic hypogonadism and low libido pending regulatory approval Monitoring & Follow-up
Monitor clinical outcomes and safety parameters in men receiving TRT for idiopathic hypogonadism Risks
Evaluate benefit-risk profile carefully before initiating TRT in this population Patient & Prescribing Data
Men with idiopathic hypogonadism and decreased libido
Emerging data suggest TRT may be safe and effective; regulatory approval pending further evidence
Clinical Best Practices
Confirm diagnosis of idiopathic hypogonadism with low testosterone and symptoms of low libido Use well-controlled clinical trial data to guide treatment decisions Engage in shared decision-making regarding potential benefits and risks of TRT Follow FDA guidance and updates on new indications for testosterone therapy Related Resources & Content
